JP2002539125A - 抗ウイルス剤としての２−ヒドロキシメチルシクロプロピリデンメチルプリンおよび−ピリミジン類 - Google Patents

抗ウイルス剤としての２−ヒドロキシメチルシクロプロピリデンメチルプリンおよび−ピリミジン類

Info

Publication number
JP2002539125A
JP2002539125A JP2000604040A JP2000604040A JP2002539125A JP 2002539125 A JP2002539125 A JP 2002539125A JP 2000604040 A JP2000604040 A JP 2000604040A JP 2000604040 A JP2000604040 A JP 2000604040A JP 2002539125 A JP2002539125 A JP 2002539125A
Authority
JP
Japan
Prior art keywords
amino
adenine
virus
compound
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000604040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539125A5 (enExample
Inventor
ゼムリツカ，ジリ
キウ，ヤオ−リング
ドラシユ，ジヨン・シー
プタク，ロジヤー・ジー
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン
ウエイン・ステイト・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン, ウエイン・ステイト・ユニバーシテイ filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン
Publication of JP2002539125A publication Critical patent/JP2002539125A/ja
Publication of JP2002539125A5 publication Critical patent/JP2002539125A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000604040A 1999-03-12 2000-03-10 抗ウイルス剤としての２−ヒドロキシメチルシクロプロピリデンメチルプリンおよび−ピリミジン類 Pending JP2002539125A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/267,839 US6352991B1 (en) 1997-01-08 1999-03-12 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
US09/267,839 1999-03-12
PCT/US2000/006250 WO2000053603A1 (en) 1999-03-12 2000-03-10 2-hydroxy methylcyclopro pylidenemethyl purines and -pyrimidines as antiviral agents

Publications (2)

Publication Number Publication Date
JP2002539125A true JP2002539125A (ja) 2002-11-19
JP2002539125A5 JP2002539125A5 (enExample) 2007-04-26

Family

ID=23020343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000604040A Pending JP2002539125A (ja) 1999-03-12 2000-03-10 抗ウイルス剤としての２−ヒドロキシメチルシクロプロピリデンメチルプリンおよび−ピリミジン類

Country Status (10)

Country Link
US (4) US6352991B1 (enExample)
EP (1) EP1165560B1 (enExample)
JP (1) JP2002539125A (enExample)
AT (1) ATE282617T1 (enExample)
CA (1) CA2366624C (enExample)
DE (1) DE60015945T2 (enExample)
DK (1) DK1165560T3 (enExample)
ES (1) ES2234579T3 (enExample)
PT (1) PT1165560E (enExample)
WO (1) WO2000053603A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021516700A (ja) * 2018-03-09 2021-07-08 メディヴィル・アクチエボラーグ （２，２−ビスヒドロキシメチル）メチレンシクロプロパンヌクレオチドを用いたがんの治療

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352991B1 (en) * 1997-01-08 2002-03-05 Wayne State University 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
AU2003267947B2 (en) * 2002-03-15 2008-11-13 The Regents Of The University Of Michigan 2,2-bis(hydroxymethyl)cyclopropylidenemethyl - purines and -pyrimidines as antiviral agents
WO2004006867A2 (en) * 2002-03-15 2004-01-22 Wayne State University 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
KR20070112464A (ko) * 2005-03-22 2007-11-26 다이이찌 산쿄 가부시키가이샤 1-알킬피롤리딘 구조를 갖는 카르바페넴 유도체의 제조방법
TWI377198B (en) * 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
US7473683B2 (en) 2005-09-14 2009-01-06 The Board Of Trustees Of The Leland Stanford Junior University Nonpolar thymidine analogs
CN101454311B (zh) * 2006-08-23 2013-03-27 卫材R&D管理有限公司 苯氧基吡啶衍生物的盐和其结晶及其制备方法
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
JP2009203226A (ja) * 2008-01-31 2009-09-10 Eisai R & D Management Co Ltd ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
US20100311972A1 (en) * 2008-02-18 2010-12-09 Mitsuo Nagai Method for producing phenoxypyridine derivative
WO2011022712A1 (en) * 2009-08-21 2011-02-24 Epiphany Biosciences, Inc. Method of treating infectious mononucleosis with acylic nucleoside derivatives
CN104892709B (zh) * 2015-06-04 2018-01-19 新乡学院 一种合成奈拉滨的方法
CN108314655B (zh) * 2018-03-29 2021-01-15 河南师范大学 一种铑催化不对称环丙化合成三元碳环嘧啶核苷类似物的方法
CN113185514A (zh) * 2021-03-11 2021-07-30 杨锦飞 一种抗乙型肝炎病毒药物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62116582A (ja) * 1985-09-24 1987-05-28 ヘキスト・アクチエンゲゼルシヤフト ６−および９−位が置換された２−アミノプリン
WO1998030563A1 (en) * 1997-01-08 1998-07-16 The Regents Of The University Of Michigan 2-hydroxymethylcyclopropyli- denemethylpurines and -pyrimidines as antiviral agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935427A (en) 1987-12-31 1990-06-19 The United States Of America As Represented By The Department Of Health And Human Services Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
US6352991B1 (en) * 1997-01-08 2002-03-05 Wayne State University 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62116582A (ja) * 1985-09-24 1987-05-28 ヘキスト・アクチエンゲゼルシヤフト ６−および９−位が置換された２−アミノプリン
WO1998030563A1 (en) * 1997-01-08 1998-07-16 The Regents Of The University Of Michigan 2-hydroxymethylcyclopropyli- denemethylpurines and -pyrimidines as antiviral agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021516700A (ja) * 2018-03-09 2021-07-08 メディヴィル・アクチエボラーグ （２，２−ビスヒドロキシメチル）メチレンシクロプロパンヌクレオチドを用いたがんの治療
JP7337855B2 (ja) 2018-03-09 2023-09-04 メディヴィル・アクチエボラーグ （２，２－ビスヒドロキシメチル）メチレンシクロプロパンヌクレオチドを用いたがんの治療

Also Published As

Publication number Publication date
DK1165560T3 (da) 2005-03-14
US6352991B1 (en) 2002-03-05
CA2366624C (en) 2007-06-12
CA2366624A1 (en) 2000-09-14
PT1165560E (pt) 2005-04-29
US6790841B2 (en) 2004-09-14
DE60015945D1 (en) 2004-12-23
EP1165560A4 (en) 2002-04-17
ES2234579T3 (es) 2005-07-01
US20050009842A1 (en) 2005-01-13
DE60015945T2 (de) 2005-11-03
WO2000053603A1 (en) 2000-09-14
EP1165560A1 (en) 2002-01-02
US6958345B2 (en) 2005-10-25
WO2000053603A9 (en) 2002-05-10
ATE282617T1 (de) 2004-12-15
US20060122203A1 (en) 2006-06-08
US20020193353A1 (en) 2002-12-19
EP1165560B1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
Ashton et al. Synthesis and antiherpetic activity of (.+-.)-9-[[(Z)-2-(hydroxymethyl) cyclopropyl] methyl] guanine and related compounds
JP2002539125A (ja) 抗ウイルス剤としての２−ヒドロキシメチルシクロプロピリデンメチルプリンおよび−ピリミジン類
Marquez et al. Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties
RU2055076C1 (ru) Бис-(гидроксиметил)-циклобутил-пурины или пиримидины и их фармацевтически приемлемые соли
EP0632048A1 (en) Phosphonate-nucleotide ester derivatives
US9174990B2 (en) 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents
US8232275B2 (en) 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and -pyrimidines as antiviral agents
Slusarchyk et al. Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl) uracil nucleoside analogs and related compounds.
WO1998030563A1 (en) 2-hydroxymethylcyclopropyli- denemethylpurines and -pyrimidines as antiviral agents
Wang et al. Synthesis of methylenecyclobutane analogues of nucleosides with axial chirality and their phosphoralaninates: a new pronucleotide effective against Epstein-Barr virus
Qin et al. Synthesis, antiviral, and antitumor activity of 2-substituted purine methylenecyclopropane analogues of nucleosides
EP0294069A2 (en) Purine compounds, process for their preparation, intermediates and pharmaceutical compositions
AU618982B2 (en) Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
JPH07126282A (ja) 新規なチオヌクレオシド誘導体
KR100192994B1 (ko) 치료용 뉴클레오시드
WO1993017035A1 (en) 2'ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070306

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080905

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025